Home » Stocks » RDY

Dr. Reddy's Laboratories Ltd. (RDY)

Stock Price: $61.10 USD -0.21 (-0.33%)
Updated Mar 8, 2021 12:30 PM EST - Market open
Market Cap 10.19B
Revenue (ttm) 2.32B
Net Income (ttm) 258.59M
Shares Out 166.07M
EPS (ttm) 1.40
PE Ratio 43.51
Forward PE 25.58
Dividend $0.29
Dividend Yield 0.48%
Trading Day March 8
Last Price $61.10
Previous Close $61.30
Change ($) -0.21
Change (%) -0.33%
Day's Open 61.17
Day's Range 60.49 - 61.33
Day's Volume 27,374
52-Week Range 33.33 - 73.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 1 week ago

New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NY...

Business Wire - 2 weeks ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ...

Benzinga - 2 weeks ago

Dr. Reddy's Laboratories Ltd (NYSE: RDY) has initiated the process with the Drugs Controller General of India for Emergency Use Authorization (EUA) of the human adenoviral vector-based platfor...

Business Wire - 2 weeks ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) toda...

PRNewsWire - 2 weeks ago

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such inve...

Business Wire - 2 weeks ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “...

Business Wire - 2 weeks ago

HYDERABAD, India and PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as...

Newsfile Corp - 2 weeks ago

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NY...

24/7 Wall Street - 1 month ago

With the trading day more than halfway over, the broad markets were pushing much higher on Tuesday.

Other stocks mentioned: ALL, CRUS, EA, Z, ZG, COLM, MCFE, PLCE, TRI
Business Wire - 1 month ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “...

PRNewsWire - 1 month ago

NEW YORK, Feb. 2, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such inves...

Zacks Investment Research - 1 month ago

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

Seeking Alpha - 1 month ago

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q3 2021 Results - Earnings Call Transcript

Business Wire - 1 month ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ...

Zacks Investment Research - 1 month ago

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

PRNewsWire - 1 month ago

KUWAIT CITY, Jan. 27, 2021 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Red...

Business Wire - 1 month ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy's”) and ...

Zacks Investment Research - 1 month ago

Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.

Business Wire - 1 month ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control Ge...

Business Wire - 1 month ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewe...

Business Wire - 1 month ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ...

Business Wire - 2 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on...

Zacks Investment Research - 2 months ago

Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.

Other stocks mentioned: BIDU, IMPUY, BCAUF, BCAUY
Business Wire - 2 months ago

HYDERABAD, India & MISSISSAUGA, Ontario & HALIFAX, Nova Scotia--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together refer...

Business Wire - 2 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as “Dr. Reddy's”) today announced the secondary listing of ...

Zacks Investment Research - 3 months ago

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

Other stocks mentioned: BHC, TEVA
Business Wire - 3 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adap...

Business Wire - 3 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) tod...

Business Wire - 3 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) tod...

Business Wire - 4 months ago

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, t...

Zacks Investment Research - 4 months ago

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

Business Wire - 4 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRA...

Seeking Alpha - 4 months ago

Dr. Reddy's Laboratories Limited (RDY) CEO Erez Israeli on Q2 2021 Results - Earnings Call Transcript

Business Wire - 4 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that Parag Agarwal will be joining the Company as Chief Financial Office...

Business Wire - 4 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter and the half year e...

Business Wire - 4 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy's”) tod...

Business Wire - 4 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, today announc...

Business Wire - 4 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, Octo...

Business Wire - 5 months ago

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, be...

Business Wire - 5 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) tod...

Business Wire - 5 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) tod...

Business Wire - 5 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr.Reddy’s”) toda...

Business Wire - 5 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) tod...

Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories.

PRNewsWire - 5 months ago

DUBAI, UAE, Sept. 23, 2020 /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) and Dr. Reddy's Laboratories (NYSE: RDY) announced that the anti-viral drug Avigan® produced ...

Zacks Investment Research - 5 months ago

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.

Other stocks mentioned: BMY
The Motley Fool - 5 months ago

Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.

Other stocks mentioned: BMY
Business Wire - 5 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr.

Other stocks mentioned: BMY
Business Wire - 5 months ago

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr.

About RDY

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1984
CEO
G. Prasad
Employees
21,650
Stock Exchange
NYSE
Ticker Symbol
RDY
Full Company Profile

Financial Performance

In 2019, RDY's revenue was 174.60 billion, an increase of 13.49% compared to the previous year's 153.85 billion. Earnings were 19.50 billion, an increase of 3.74%.

Financial numbers in millions INR.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is 72.50, which is an increase of 18.67% from the latest price.

Price Target
$72.50
(18.67% upside)
Analyst Consensus: Buy